977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer
Herbst R, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. 977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. European Journal Of Cancer Supplements 2003, 1: s293. DOI: 10.1016/s1359-6349(03)91004-4.Peer-Reviewed Original ResearchAngiogenesis, Metastasis, and Lung Cancer
Onn A, Herbst RS. Angiogenesis, Metastasis, and Lung Cancer. Methods In Molecular Medicine 2003, 74: 329-348. PMID: 12415706, DOI: 10.1385/1-59259-323-2:329.Peer-Reviewed Original ResearchConceptsNew blood vesselsBlood vesselsBlood supplyTumor angiogenesisPre-existing tumorsAdequate blood supplyNegative regulatory moleculeAnti-angiogenesis drugsInduction of angiogenesisMost patientsInitial treatmentConventional therapyDetectable metastasesLung cancerMost deathsCancer resultsMetastasisTumorsAngiogenesisStriking increaseCancer biologyCancerNormal cellsTerm angiogenesisHost cells